Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 1.00 |
| ▸ | PTGES | O14684 | 2/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | DLAT | P10515 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | ACHE | P22303 | 13/20 | 0.56 |
| ▸ | MET | P08581 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14837010 | 0.85 | SIRT2 (1.00) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL8168239 | 0.85 | SIRT2 (1.00) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL15557965 | 0.85 | SIRT2 (1.00) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL15694978 | 0.85 | SIRT2 (1.00) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL6135673 | 0.84 | SIRT2 (0.72) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL14233249 | 0.82 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL98723 | 0.82 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL21907266 | 0.82 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL14577497 | 0.82 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 | |
| SCHEMBL12634392 | 0.82 | SIRT2 (0.86) | SIRT2SIRT1PTGESSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096952-A1 | SCAFFOLDS AND SCAFFOLD HOLDERS FOR TISSUE ENGINEERING | UNIVERSITY OF CONNECTICUT (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250114344-A1 | COMBINATORIAL PHARMACOTHERAPY FOR THE RESTORATION OF NEURO-FUNCTION AND COMBINATORIAL PHARMACOLOGICAL COMPOSITION THEREFORE | NEURO INNOVATORS LLC (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025017469-A1 | PSYCHEDELIC \"BRAIN BOOST\" COMBINATIONS FOR ENHANCING CELLULAR ENERGY PRODUCTION | FEILDING AMANDA (GB) | 2025-01-23 | — | — | WO | disclosed |
| US-20240398651-A1 | ISCHEMIC STROKE REHABILITATION PROTOCOL IMPLEMENTING ROBOTIC ASSISTED REHABILITATION IN SUBJECTS WITH PHARMACOLOGICALLY INDUCED NEUROPLASTICITY AND OTHER CONDITION-BASED TARGETED SYNAPTIC REBUILDING OR ENHANCEMENT PROTOCOLS IMPLEMENTING ROBOTIC ELECTRICAL AND ELECTROMAGNETIC STIMULI IN SUBJECTS WITH PHARMACOLOGICALLY INDUCED NEUROPLASTICITY | NEURO-INNOVATORS, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2023205369-A1 | COMBINATORIAL PHARMACOTHERAPY FOR THE RESTORATION OF NEURO-FUNCTION AND COMBINATORIAL PHARMACOLOGICAL COMPOSITION THEREFORE | NEURO-INNOVATORS, LLC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11744820-B2 | Inhibitors of microbially induced amyloid | AXIAL THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023097123-A1 | ISCHEMIC STROKE REHABILITATION PROTOCOL IMPLEMENTING ROBOTIC ASSISTED REHABILITATION IN SUBJECTS WITH PHARMACOLOGICALLY INDUCED NEUROPLASTICITY AND OTHER CONDITION- BASED TARGETED SYNAPTIC REBUILDING OR ENHANCEMENT PROTOCOLS IMPLEMENTING ROBOTIC ELECTRICAL AND ELECTROMAGNETIC STIMULI IN SUBJECTS WITH PHARMACOLOGICALLY INDUCED NEUROPLASTICITY | NEURO-INNOVATORS, LLC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20220040145-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744820-B2 | Inhibitors of microbially induced amyloid | APP, PSEN1, BACE1 | SIRT2 4487/4885SIRT1 3856/4885PTGES 948/4885 |
| US-20220040145-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | APP, PSEN1, BACE1 | SIRT2 4487/4885SIRT1 3856/4885PTGES 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.